News

December 03, 2009
ImmunoGen, Inc. Announces Conference Call to Discuss Clinical Data Reported at Recent Medical Meetings

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 3, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will hold a conference call at 8:00 a.m. ET on Monday, December 14, 2009, to review the clinical data reported on TAP compounds at the AACR-NCI-EORTC, American Society of Hematology, and San Antonio Breast Cancer Symposium medical meetings held in November/December 2009. This call will include comments by ImmunoGen’s Chief Executive Officer, Daniel Junius, Chief Medical Officer, James O’Leary, MD, and Chief Scientific Officer, John Lambert, PhD.

To access the live call by phone, dial 913-312-1426. Passcode is 3466172. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through December 28, 2009.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

Source: ImmunoGen, Inc.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?